Investors
IR News
- Feb 04, 2021 Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance
- Feb 04, 2021 (Timely Disclosure) Notice of Commencement of Preparation for Transition to a Holding Company and Change in Fiscal Year
- Feb 02, 2021 Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension
Management Policies
- CEO Message
- CORE PRINCIPLE / WORLD VISION
- Santen 2030
- Medium Term Management Plan
- Corporate Governance
- Disclosure Policy
- Forward-Looking Statement
IR Library
- Consolidated Performance
- Presentation Materials · videos
- Integrated Report (Annual Report)
- Data Book
- Pipeline
- Materials for the General Meeting of Shareholders
